Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Apoptosis. 2000 Oct;5(4):315-8.

Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

Author information

  • Molecular Biology Laboratory, Hospital Universitario Marques de, Valdecilla, Santander, Spain. inmflj@humv.es

Abstract

Chronic myelogenous leukemia (CML) cells are highly resistant to apoptosis induced by chemotherapeutic drugs. The observation that production of Bcr-Abl is the initiating event in CML has focussed attention on the survival signals triggered by this oncogene. A number of signal transducers and transcription factors have been associated with the antiapoptotic phenotype of CML cells, some of which lead to the expression and/or activation of members of the Bcl-2 family of apoptosis modulators, such as Bcl-xL and Bad. In this article, recent advances in understanding the antiapoptotic pathways triggered by Bcr-Abl in CML cells, are discussed.

PMID:
11227211
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk